Preventing Disease Recurrence with Adjuvant Therapy in Stage IIB/IIC Melanoma

Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Neda Shahriari, MD

This study assessed the link between depressive symptoms in real-world patients with psoriasis to help identify characteristics for those at risk. What were the findings? To learn more, join Dr. Charles Turck as he speaks with Dr. Neda Shahriari, Board-Certified Dermatologist at Brigham and Women’s Hospital in Boston, Massachusetts.

Host: Raj Chovatiya, MD, PhD
Guest: Steven R. Feldman, MD, PhD

To gain a better understanding of the different treatment attributes that patients with moderate-to-severe atopic dermatitis value most, a discrete choice experiment was conducted. And now, the results are in, with itch control being the top attribute. Joining Dr. Raj Chovatiya to share this and other key findings from his research that was featured as a poster at the 2023 Fall Clinical Dermatology conference is Dr. Steven Feldman, Professor of Dermatology, Pathology, Social Sciences, and Health Policy at the Wake Forest University School of Medicine in Winston-Salem, North Carolina.

Host: Raj Chovatiya, MD, PhD
Guest: Melinda Gooderham, MSc, MD, FRCPC

Due to the evolving treatment landscape, the way we think about treating adult and elderly patients with atopic dermatitis has shifted. So what are some special considerations we need to think about when selecting a treatment option for long-term control, and how can we best involve patients in the decision-making process? Joining Dr. Raj Chovatiya to help answer these and other key questions in atopic dermatitis care is Dr. Melinda Gooderham, Medical Director for the SKiN Center for Dermatology in Peterborough, Ontario.

Host: Raj Chovatiya, MD, PhD
Guest: Steven R. Feldman, MD, PhD

The biologics we know are revolutionary treatments for our patients with psoriasis and now other inflammatory skin diseases. So how do biosimilars play a part in the evolving treatment of psoriasis? Learn more with Dr. Raj Chovatiya as he dives further into biosimilars with Dr. Steve Feldman, Professor of Dermatology, Pathology, Social Sciences, and Health Policy at the Wake Forest University School of Medicine in Winston-Salem, North Carolina.

Host: Raj Chovatiya, MD, PhD
Guest: Matthew Zirwas, MD
Guest: Douglas DiRuggiero, DMSc, PA-C

When managing atopic dermatitis, it’s up to the patient to determine how much therapeutic intervention they want to pursue, which underscores the importance of applying shared decision-making to practice. Joining Dr. Raj Chovatiya to share their perspectives on how we can utilize shared decision-making in atopic dermatitis care are Dr. Matthew Zirwas and Mr. Douglas DiRuggiero. Dr. Zirwas founded Bexley Dermatology Research Clinic in Columbus, Ohio where he specializes in adult eczema, and Mr. DiRuggiero is a certified physician assistant at the Skin Cancer and Cosmetic Dermatology Center in Rome, Georgia.

Host: Raj Chovatiya, MD, PhD
Guest: George Han, MD, PhD

The discovery of the IL-23 pathway has revolutionized the treatment of psoriasis. Learn more about the current state of IL-23 inhibition in psoriasis management with Dr. Raj Chovatiya and Dr. George Han, Associate Professor in the Department of Dermatology at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell in Uniondale, New York.

Host: Raj Chovatiya, MD, PhD
Guest: Jennifer Soung, MD
Guest: Einjuan James Song, MD, FAAD

The atopic dermatitis treatment landscape has evolved over the past several years. To catch up on the current treatment options available and the novel therapies in development, Dr. Raj Chovatiya speaks with Drs. James Song and Jennifer Soung. Dr. Song is the Director of Clinical Research for Frontier Dermatology Partners in Everett, Washington, and Dr. Soung is the Director of Clinical Research at Southern California Dermatology in Santa Ana, California.

Host: Raj Chovatiya, MD, PhD
Guest: George Han, MD, PhD

Our understanding of TYK2’s role in the pathophysiology of psoriasis has recently evolved, leading to new treatment options like deucravacitinib. Deucravacitinib is the first approved TYK2 inhibitor approved for moderate to severe plaque psoriasis. Learn more about this treatment option and the role of TYK2 with Dr. Raj Chovatiya and Dr. George Han, Associate Professor in the Department of Dermatology at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell in Uniondale, New York.

Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Jonathan Silverberg, MD, PhD, MPH

Atopic dermatitis is more than a disease of the skin. It’s a complex and heterogeneous inflammatory disease mediated by multiple T-cell–driven inflammatory pathways, like the OX40 pathway, leading to chronic and persistent symptoms and significant burden.^1-4 Explore the heterogeneity of atopic dermatitis and the importance of OX40 signaling in disease pathogenesis with Dr Charles Turck and Dr. Jonathan Silverberg, Professor and Director of Clinical Research and the Director of Patch Testing at George Washington University School of Medicine and Health Sciences.

References:

1. Silverberg JI. Clinical Management of Atopic Dermatitis. 1st ed. 2018.
2. Ratchataswan T, et al. J Allergy Clin Immunol Pract. 2021;9:1053-1065.
3. Weidinger S, et al. Nat Rev Dis Primers. 2018;4:1.
4. De Bruyn Carlier T, et al. J Autoimmun. 2021;120:102634.

©2023 Amgen Inc. All rights reserved. USA-451-80031 8/23

Host: Raj Chovatiya, MD, PhD
Guest: Jason E. Hawkes, MD, MS, FAAD

Generalized pustular psoriasis is a rare inflammatory skin disease that can be life-threatening if left untreated, and treatment typically involves the use of therapies approved for plaque psoriasis. However, that could all be changing thanks to the recent understanding of IL-36’s role in generalized pustular psoriasis and the development of the treatment option spesolimab. Learn more with Dr. Raj Chovatiya and Dr. Jason Hawkes, medical dermatologist in the Greater Sacramento area who also sits on the National Psoriasis Foundation Medical Board and Scientific Advisory Committee.